^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCND1 overexpression

    i
    Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
    Entrez ID:
    595
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    11ms
    Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jun 2025
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Copiktra (duvelisib) • ETP-47187
    11ms
    SQSTM1/p62 predicts prognosis and upregulates the transcription of CCND1 to promote proliferation in mantle cell lymphoma. (PubMed, Protoplasma)
    The precise targeting of p62 therapy reduces the promoting effect of Nrf2 on CCND1, thereby preventing cell cycle progression and effectively inhibiting tumor proliferation. Therefore, p62 may provide a potential target for MCL.
    Journal
    |
    CCND1 (Cyclin D1) • SQSTM1 (Sequestosome 1)
    |
    CCND1 overexpression
    11ms
    A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=7, Terminated, AstraZeneca | Phase classification: P1/2 --> P1
    Phase classification
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    AZD0466
    11ms
    EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=622, Recruiting, Genmab | Trial completion date:Jun 2031 --> Nov 2032 | Trial primary completion date: Jun 2031 --> Nov 2032
    Trial completion date • Trial primary completion date • Adverse events
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
    12ms
    CAPITAL: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=30, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Oct 2024
    Trial completion • Trial completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Truqap (capivasertib)
    12ms
    Unlocking the role of miR-17: Driving G1-S cell cycle transition in oral tongue cancer through integrated bioinformatics and laboratory analyses. (PubMed, Arch Oral Biol)
    The findings suggest that miR-17 may regulate the G1-S transition of the cell cycle in oral tongue cancer. Further validation and functional studies are warranted to confirm their role as biomarkers.
    Journal
    |
    CCND1 (Cyclin D1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • MIR17 (MicroRNA 17)
    |
    CCND1 overexpression
    1year
    EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=622, Recruiting, Genmab | Trial completion date: Nov 2032 --> Jun 2031 | Trial primary completion date: Nov 2032 --> Jun 2031
    Trial completion date • Trial primary completion date • Adverse events • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
    1year
    Downregulation of lncRNA-MALAT1, Altered Immunohistochemical Expression of Cyclin D1 Protein and E-Cadherin Protein in Correlation to Meningioma Grades. (PubMed, Asian Pac J Cancer Prev)
    lncRNA MALAT1 is downregulated in meningiomas and associated with increased aggressiveness. Overexpressed cyclin D1 and decreased E-cadherin expression are also associated with high grade meningioma.
    Journal
    |
    CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
    |
    CCND1 overexpression • CCND1 expression • CDH1 expression
    1year
    Cyclin D1-negative Mantle Cell Lymphoma. (PubMed, Hum Pathol)
    We then discuss currently available diagnostic approaches and we conclude with future directions. We also suggest that the more specific terms CCND2-rearranged MCL or CCND3-rearranged MCL be used for neoplasms in which the rearranged gene is known, and that we reserve the term cyclin D1-negative MCL for neoplasms in which the rearranged gene in unknown.
    Review • Journal
    |
    CCND1 (Cyclin D1) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3)
    |
    Chr t(11;14) • CCND1 overexpression
    1year
    topMIND: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=54, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Pan tumor
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
    |
    parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
    1year
    EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=622, Recruiting, Genmab | Trial completion date: Jun 2031 --> Nov 2032 | Trial primary completion date: Jun 2031 --> Nov 2032
    Trial completion date • Trial primary completion date • Adverse events • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
    1year
    Evaluation of Cyclin D1 protein and its association with the clinicopathological characteristics and prognosis of lung cancer: A retrospective study from Southern Kerala, India. (PubMed, Lung India)
    Cyclin D1 expression was associated with histology type of lung cancer with no significant association to prognosis.
    Retrospective data • Journal
    |
    CCND1 (Cyclin D1)
    |
    CCND1 overexpression